H.C. Wainwright analyst Matthew Caufield initiated coverage of Immunic (IMUX) with a Buy rating and $10 price target The firm likes the company’s “comprehensive” neuroprotective and anti-inflammatory approach to both relapsing and progressive multiple sclerosis. The positive Phase 3 ENSURE interim analysis “is de-risking in relapsing MS,” the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX: